title: Normal inflammasome activation and low production of IL-23 by monocyte-derived macrophages from subjects with a history of reactive arthritis.
abstract: OBJECTIVE
  The pathogenesis of reactive arthritis (ReA) is incompletely understood but may involve aberration(s) in the host's innate immune response towards infecting microbes. We therefore studied the production of interleukin (IL)-1β, a marker of inflammasome activation, and of IL-6, IL-12, IL-23, and tumour necrosis factor (TNF)-α, promoters of T-cell differentiation, by peripheral blood mononuclear cells (PBMNs) and monocyte-derived macrophages from healthy subjects with a history of ReA.
  
  
  METHODS
  The study included 10 human leucocyte antigen (HLA)-B27-positive healthy subjects with previous ReA triggered by Yersinia enterocolitica O:3 infection and 20 healthy reference subjects, of whom 10 were HLA-B27 positive. PBMNs and macrophages were cultured for 18 h with bacterial lipopolysaccharide (LPS), muramyl dipeptide (MDP), Yersinia, or their appropriate combinations. PBMNs were also stimulated with monosodium urate (MSU) crystals. Cytokine levels were measured using an enzyme-linked immunosorbent assay (ELISA) and the Luminex system.
  
  
  RESULTS
  IL-1β secretion was similar from cells of the ReA group and from the HLA-B27-positive and -negative reference groups. TNF-α production from macrophages upon co-stimulation of LPS and MDP increased in the order ReA group < HLA-B27-positive reference group < HLA-B27-negative reference group (p for a trend = 0.027). Similarly, Yersinia-induced TNF-α and IL-23 production increased in the same order (p for trend for TNF-α = 0.036; p for trend for IL-23 = 0.026).
  
  
  CONCLUSIONS
  PBMNs and macrophages from healthy subjects with previous ReA show normal inflammasome activation and low TNF-α and IL-23 production. This low cytokine production may impair bacterial elimination and thereby contribute to the triggering of ReA.
authors: Unit of Immunotoxicology, Finnish Institute of Occupational Health, Helsinki, Finland. elina.valimaki@helsinki.fi
authors: E
authors: E
authors: Välimäki
authors: S
authors: S
authors: Aittomäki
authors: L
authors: L
authors: Karenko
authors: J
authors: J
authors: Kantonen
authors: T
authors: T
authors: Pettersson
authors: U
authors: U
authors: Turunen
authors: S
authors: S
authors: Matikainen
authors: M
authors: M
authors: Leirisalo-Repo
authors: H
authors: H
authors: Repo
mesh_terms: D000293:Adolescent; D000328:Adult; D016918:Arthritis, Reactive / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D015415:Biomarkers / Q000378:metabolism; D002648:Child; D015331:Cohort Studies; D004789:Enzyme Activation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015796:HLA-B27 Antigen / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D058847:Inflammasomes / Q000276:immunology / Q000378:metabolism*; D018664:Interleukin-12 / Q000276:immunology / Q000378:metabolism; D053759:Interleukin-23 / Q000276:immunology* / Q000378:metabolism; D015850:Interleukin-6 / Q000276:immunology / Q000378:metabolism; D008264:Macrophages / Q000276:immunology / Q000473:pathology; D008297:Male; D000091402:Prohibitins; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism; D015009:Yersinia Infections / Q000150:complications / Q000175:diagnosis*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D015796:HLA-B27 Antigen; D058847:Inflammasomes; D053759:Interleukin-23; D015850:Interleukin-6; C000717331:PHB2 protein, human; D000091402:Prohibitins; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12